2015年3月10日 讯/生物谷BIOON/ --基于单克隆抗体的生物药已成为首选治疗各种癌症的药物，尤其是对于血液肿瘤（白血病）。各种癌症发病率的上升，日益流行的先进疗法（生物和靶向药物疗法），主要药物的专利期满以及商业化的仿制药物这几个因素推动了全球肿瘤药物市场的增长。
然而，高成本的新药开发、失败的风险以及癌症治疗相关的副作用会限制市场的增长。诸如靶向疗法和免疫疗法等商业化的先进疗法将减少负面因素的制约并点燃整个市场。
预计到2020年全球肿瘤市场将达到1119亿美元。几个关键药物如赫赛汀、爱必妥、美罗华、阿瓦斯丁的专利到期可促进生物仿制药品的发展。进一步讲，生物疗法由于其本身的高效性、靶向性和低毒性等优点，预计在2020年会主导整个市场。由于治疗血液肿瘤免疫疗法药物的高成本，血液肿瘤药物市场在2013年是最大的收入部分。
从全球市场分布来看，北美占绝对的主导地位，其次是欧洲。2013年，由于跨国公司在抗癌药物方面的研究和开发带来的巨额投资，尤其是免疫疗法，有利的医保政策以及高使用率的免疫治疗，北美总共约占到全球38%的市场份额。另一方面，亚太市场增速将在预测期间达到8.7%的复合年增长率。如此高的增长主要是由于对免疫疗法等先进疗法意识的增加和人均医疗保健支出的增加。
报告中涉及的主要公司有罗氏、诺华、新基、阿斯利康、强生、默克、礼来和葛兰素史克。在抗肿瘤药物市场运作的公司关注合作、获批和收购等战略。
生物谷推荐英文原文报道：
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types， especially for blood cancer (leukemia). Rising incidence of various cancer conditions， growing popularity of advance therapies (biological and targeted drug therapies)， patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. However， high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies would restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the market growth.
The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin， Erbitux， Rituxan and Avastin， is expected to boost the growth of cancer biosimilars market by 2020. Going further， the biological therapies are expected to dominate the market by 2020， due to their high efficacy， target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.
Geographically， North America， dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs， particularly immune therapeutics， favorable reimbursement policies， and high adoption rate of immunotherapies. On the other hand， Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.
Key companies profiled in the report are Roche diagnostics， Novartis AG， Celgene Corporation， AstraZeneca， Johnson & Johnson， Merck & Co.， Eli Lilly & Co. and GlaxoSmithKline. Companies operating in the cancer drugs market focus on several strategies such as collaboration， approval and acquisition.